Supernus Pharmaceuticals, Inc. (SUPN) News
Filter SUPN News Items
SUPN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SUPN News Highlights
- SUPN's 30 day story count now stands at 2.
- Over the past 4 days, the trend for SUPN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- CNS, DEC and EYE are the most mentioned tickers in articles about SUPN.
Latest SUPN News From Around the Web
Below are the latest news stories about SUPERNUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SUPN as an investment opportunity.
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in CanadaMONTREAL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) ("Supernus"), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, granting Knight the rights to seek regulatory approval and commercialize Q |
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy PotentialThe increased understanding and widespread acceptance of mental health concerns have put psychedelic stocks in the spotlight. |
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 8.7% CAGR over the last three yearsIt hasn't been the best quarter for Supernus Pharmaceuticals, Inc. ( NASDAQ:SUPN ) shareholders, since the share price... |
Insider Sell Alert: Director Frederick Hudson Sells 9,093 Shares of Supernus Pharmaceuticals ...Supernus Pharmaceuticals Inc (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, has recently seen a significant insider sell by one of its directors. |
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2023 Earnings Call TranscriptSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2023 Earnings Call Transcript November 8, 2023 Supernus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.24, expectations were $0.13. Operator: Good afternoon, and welcome to Supernus Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a […] |
Q3 2023 Supernus Pharmaceuticals Inc Earnings CallQ3 2023 Supernus Pharmaceuticals Inc Earnings Call |
Supernus (SUPN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesThe headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
Supernus Pharmaceuticals (SUPN) Reports Q3 Loss, Tops Revenue EstimatesSupernus (SUPN) delivered earnings and revenue surprises of -323.08% and 8.74%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
Supernus Announces Third Quarter 2023 Financial ResultsRaises full year 2023 adjusted operating earnings (non-GAAP)(1) guidance range to $95 million to $110 million from previous range of $75 million to $100 millionTotal revenues (GAAP) of $153.9 million in the third quarter of 2023; total revenues excluding Trokendi XR® net product sales (non-GAAP)(2), increased by 24% in the third quarter of 2023, compared to the same period in 2022Qelbree® net product sales of $37.1 million in the third quarter of 2023, a 103% increase compared to the third quart |
Supernus to Participate in the Jefferies London Healthcare ConferenceROCKVILLE, Md., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15, 2023, at 9:00 a.m. ET (2:00 p.m. GMT) at the Waldorf Hilton, London, UK. |